罗欣药业：预计2025年第一季度净利润500万元-700万元，扭亏为盈

Core Viewpoint - 罗欣药业 is expected to report a significant improvement in net profit for the first quarter of 2025, transitioning from a loss in the previous year to a profit range of 5 million to 7 million yuan [1] Financial Performance - The estimated net profit attributable to shareholders is projected to be between 5 million and 7 million yuan, compared to a loss of 36.66 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 500,000 and 700,000 yuan, up from a loss of 38.96 million yuan year-on-year [1] - Basic earnings per share are forecasted at 0.01 yuan, a recovery from a loss of 0.03 yuan per share in the previous year [1] Market Performance - The market share of the innovative drug,替戈拉生片, has significantly increased, with sales volume showing a year-on-year growth [1]